
First patient receives novel heavy-chain-only antibody
Cancer Research UK and KisoJi Biotechnology have launched a new Phase I/IIa clinical trial for people with selected TROP2-expressing solid tumours. The study will evaluate the effectiveness and safety of KisoJi’s lead asset, KJ-103, a naked anti-TROP2 antibody. TROP2 is a transmembrane glycoprotein involved in… Read More















